CenterForBiosimilars
3 FOLLOWERS
The Center for Biosimilars is your online resource for emerging technologies, with a focus on improving critical thinking in the field to impact patient outcomes. We'll discuss the current landscape for advanced health care management-reviewing emerging treatment paradigms, approaches, and considerations all by authoritative industry voices.
CenterForBiosimilars
2h ago
A real-world study in Spain on inflammatory bowel disease (IBD) patients found no meaningful changes in clinical or biochemical markers or differences in effectiveness between the adalimumab originator and the biosimilar MSB11022 (Idacio; Fresenius Kabi) in adalimumab-naïve patients ..read more
CenterForBiosimilars
17h ago
Colin C. Edgerton, MD, discusses key considerations for utilizing biosimilars in the bone health treatment landscape ..read more
CenterForBiosimilars
1d ago
Here are the top 5 biosimilar articles for the week of May 13, 2024 ..read more
CenterForBiosimilars
2d ago
Two posters from the Academy of Managed Care Pharmacy’s annual meeting provided hope that despite low uptake so far, adalimumab biosimilars can deliver on the promise of comparable safety and efficacy with the originator in multiple disease states, as well as cost savings ..read more
CenterForBiosimilars
3d ago
At the Festival of Biologics USA, panelists stressed the need for patient-centered communication and education to boost comfort with biosimilars, emphasizing consistent support from health care providers despite restrictive payer policies ..read more
CenterForBiosimilars
5d ago
A Korean survey found that while most oncologists believe biosimilars are just as safe and effective as originator drugs, they often prescribe the originators due to factors like lack of patient trust in biosimilars and lower than expected cost savings ..read more
CenterForBiosimilars
6d ago
Jeffrey Casberg, RPh, MS, examines upcoming generic and biosimilar competition in the pharmaceutical industry, predicting certain drugs that will face competition soon ..read more
CenterForBiosimilars
1w ago
In Canada, a study on inflammatory bowel disease (IBD) patients switching to infliximab or adalimumab biosimilars found no change in clinical remission or antidrug antibodies after 24 weeks, but 13% experienced the nocebo effect, leading to one-fifth discontinuing biosimilar therapy ..read more
CenterForBiosimilars
1w ago
Expert providers in inflammatory diseases provide additional resources on biosimilars and adalimumab biosimilar for patients and providers ..read more
CenterForBiosimilars
1w ago
Providers in inflammatory diseases discuss the instrumental role nurses and support staff play in educating patients on adalimumab biosimilars ..read more